Ionis Pharmaceuticals (IONS) Stock Forecast, Price Target & Predictions
IONS Stock Forecast
Ionis Pharmaceuticals stock forecast is as follows: an average price target of $51.68 (represents a 52.27% upside from IONS’s last price of $33.94) and a rating consensus of 'Buy', based on 18 wall street analysts offering a 1-year stock forecast.
IONS Price Target
The average price target for Ionis Pharmaceuticals (IONS) is $51.68 based on 1-year price targets from 18 Wall Street analysts in the past 3 months, with a price target range of $77.00 to $28.00. This represents a potential 52.27% upside from IONS's last price of $33.94.
IONS Analyst Ratings
According to 18 Wall Street analysts, Ionis Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for IONS stock is 0 'Strong Buy' (0.00%), 9 'Buy' (50.00%), 8 'Hold' (44.44%), 1 'Sell' (5.56%), and 0 'Strong Sell' (0.00%).
Ionis Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 09, 2024 | Debjit Chattopadhyay | Guggenheim | $65.00 | $37.80 | 71.96% | 91.51% |
| Aug 02, 2024 | Kostas Biliouris | BMO Capital | $60.00 | $51.32 | 16.91% | 76.78% |
| Jul 24, 2024 | Mani Foroohar | Leerink Partners | $62.00 | $51.86 | 19.55% | 82.68% |
| Jul 22, 2024 | Akash Tewari | Jefferies | $77.00 | $50.61 | 52.14% | 126.87% |
| Jul 22, 2024 | Salveen Richter | Goldman Sachs | $33.00 | $50.61 | -34.80% | -2.77% |
| Jul 16, 2024 | Akash Tewari | Jefferies | $75.00 | $49.84 | 50.48% | 120.98% |
| Jun 27, 2024 | Paul Matteis | Stifel Nicolaus | $53.00 | $47.70 | 11.11% | 56.16% |
| Jun 17, 2024 | Luca Issi | RBC Capital | $70.00 | $40.63 | 72.29% | 106.25% |
| Jun 14, 2024 | William Pickering | Tudor Pickering | $44.00 | $41.12 | 7.00% | 29.64% |
| May 17, 2024 | Kostas Biliouris | BMO Capital | $67.00 | $36.84 | 81.87% | 97.41% |
The latest Ionis Pharmaceuticals stock forecast, released on Oct 09, 2024 by Debjit Chattopadhyay from Guggenheim, set a price target of $65.00, which represents a 71.96% increase from the stock price at the time of the forecast ($37.80), and a 91.51% increase from IONS last price ($33.94).
Ionis Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 10 |
| Avg Price Target | - | $65.00 | $60.60 |
| Last Closing Price | $33.94 | $33.94 | $33.94 |
| Upside/Downside | -100.00% | 91.51% | 78.55% |
In the current month, the average price target of Ionis Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Ionis Pharmaceuticals's last price of $33.94. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 09, 2024 | Guggenheim | Buy | Buy | Hold |
| Sep 26, 2024 | RBC Capital | Market Perform | Market Perform | Hold |
| Sep 26, 2024 | Needham | Underperform | Underperform | Hold |
| Aug 26, 2024 | Needham | Market Perform | Market Perform | Hold |
| Aug 02, 2024 | Wells Fargo | Market Perform | Market Perform | Hold |
| Aug 02, 2024 | BMO Capital | Outperform | Market Perform | Downgrade |
| Jul 24, 2024 | Leerink Partners | - | Outperform | Upgrade |
| Jul 22, 2024 | Jefferies | Buy | Buy | Hold |
| Jul 22, 2024 | William Blair | Outperform | Outperform | Hold |
| Jul 22, 2024 | Goldman Sachs | Sell | Sell | Hold |
Ionis Pharmaceuticals's last stock rating was published by Guggenheim on Oct 09, 2024. The company gave IONS a "Buy" rating, the same as its previous rate.
Ionis Pharmaceuticals Financial Forecast
Ionis Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $144.21M | $188.41M | $131.00M | $152.00M | $159.77M | $133.79M | $141.92M | $440.01M | $133.09M | $125.75M | $111.61M | $290.28M | $160.08M | $145.54M | $133.37M | $493.68M | $167.89M | $163.81M | $297.21M | $144.42M | $110.30M |
| Avg Forecast | $214.02M | $159.11M | $151.64M | $132.58M | $141.30M | $129.57M | $156.09M | $131.42M | $174.12M | $136.86M | $140.44M | $128.15M | $160.13M | $143.95M | $140.54M | $122.46M | $275.55M | $160.15M | $129.16M | $128.62M | $274.46M | $182.14M | $148.87M | $161.13M | $407.05M | $153.80M | $145.31M | $285.38M | $433.26M | $183.84M |
| High Forecast | $273.49M | $203.32M | $193.78M | $152.81M | $193.05M | $133.30M | $157.96M | $131.42M | $207.03M | $166.52M | $179.46M | $163.76M | $204.62M | $143.95M | $140.54M | $122.46M | $275.55M | $160.15M | $129.16M | $128.62M | $274.46M | $182.14M | $148.87M | $161.13M | $407.05M | $153.80M | $145.31M | $285.38M | $519.91M | $220.61M |
| Low Forecast | $168.23M | $125.07M | $119.20M | $99.38M | $114.09M | $125.84M | $154.22M | $131.42M | $128.03M | $121.42M | $110.39M | $100.73M | $125.86M | $143.95M | $140.54M | $122.46M | $275.55M | $160.15M | $129.16M | $128.62M | $274.46M | $182.14M | $148.87M | $161.13M | $407.05M | $153.80M | $145.31M | $285.38M | $346.61M | $147.07M |
| # Analysts | 3 | 3 | 3 | 5 | 14 | 9 | 7 | 4 | 9 | 15 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 7 | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.05% | 1.34% | 1.02% | 0.95% | 1.11% | 0.95% | 1.16% | 1.60% | 0.83% | 0.97% | 0.87% | 1.06% | 0.88% | 0.98% | 0.83% | 1.21% | 1.09% | 1.13% | 1.04% | 0.33% | 0.60% |
Ionis Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 9 analysts is $174.12M, with a low forecast of $128.03M, and a high forecast of $207.03M. IONS's average Quarter revenue forecast represents a 20.75% increase compared to the company's last Quarter revenue of $144.21M (Sep 23).
Ionis Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 14 | 9 | 7 | 4 | 9 | 15 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 7 | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-143.26M | $-90.19M | $-97.00M | $-358.00M | $-50.69M | $-94.06M | $-53.74M | $227.09M | $-76.73M | $-73.18M | $-83.38M | $-6.42M | $-12.52M | $-17.08M | $-36.38M | $236.16M | $26.93M | $8.69M | $130.63M | $12.34M | $17.20M |
| Avg Forecast | $-19.77M | $-14.70M | $-14.01M | $-12.25M | $-13.05M | $-11.97M | $-14.42M | $-109.83M | $-16.08M | $-12.64M | $-12.97M | $-99.85M | $-14.79M | $-37.47M | $-36.58M | $-78.93M | $-71.73M | $-41.69M | $-33.62M | $-64.14M | $-71.44M | $-47.41M | $-38.75M | $-33.35M | $-105.96M | $-40.03M | $-37.83M | $123.99M | $18.51M | $21.68M |
| High Forecast | $-15.54M | $-11.55M | $-11.01M | $-9.18M | $-10.54M | $-11.62M | $-14.25M | $-87.87M | $-11.83M | $-11.22M | $-10.20M | $-79.88M | $-11.63M | $-37.47M | $-36.58M | $-63.14M | $-71.73M | $-41.69M | $-33.62M | $-51.31M | $-71.44M | $-47.41M | $-38.75M | $-26.68M | $-105.96M | $-40.03M | $-37.83M | $148.79M | $22.21M | $26.01M |
| Low Forecast | $-25.26M | $-18.78M | $-17.90M | $-14.12M | $-17.83M | $-12.31M | $-14.59M | $-131.80M | $-19.12M | $-15.38M | $-16.58M | $-119.82M | $-18.90M | $-37.47M | $-36.58M | $-94.72M | $-71.73M | $-41.69M | $-33.62M | $-76.97M | $-71.44M | $-47.41M | $-38.75M | $-40.02M | $-105.96M | $-40.03M | $-37.83M | $99.19M | $14.81M | $17.34M |
| Surprise % | - | - | - | - | - | - | - | - | - | 11.33% | 6.95% | 0.97% | 24.20% | 1.35% | 2.57% | 0.68% | -3.17% | 1.84% | 2.18% | 1.30% | 0.09% | 0.26% | 0.44% | 1.09% | -2.23% | -0.67% | -0.23% | 1.05% | 0.67% | 0.79% |
13 analysts predict IONS's average Quarter EBITDA for Mar 22 to be $-78.93M, with a high of $-63.14M and a low of $-94.72M. This is -134.76% lower than Ionis Pharmaceuticals's previous annual EBITDA (Dec 21) of $227.09M.
Ionis Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 14 | 9 | 7 | 4 | 9 | 15 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 7 | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 | 15 |
| Net Income | - | - | - | - | - | - | - | - | - | $-147.41M | $-85.29M | $-124.00M | $-52.00M | $-46.99M | $-105.14M | $-65.17M | $224.61M | $-82.47M | $-80.88M | $-89.87M | $-340.27M | $-30.94M | $-31.84M | $-48.23M | $184.42M | $26.16M | $-876.00K | $84.44M | $-1.42M | $3.47M |
| Avg Forecast | $-124.96M | $-151.38M | $-158.03M | $-164.27M | $-162.98M | $-167.27M | $-137.46M | $-122.61M | $-118.95M | $-149.83M | $-131.20M | $-111.46M | $573.79M | $-105.57M | $-89.04M | $-88.11M | $-6.38M | $-71.16M | $-80.98M | $-69.13M | $37.77M | $-18.93M | $-37.73M | $-44.21M | $140.04M | $-44.37M | $-40.14M | $80.15M | $-2.13M | $4.37M |
| High Forecast | $-90.20M | $-109.27M | $-114.07M | $-147.13M | $-107.10M | $-120.74M | $-99.22M | $-98.08M | $-42.70M | $-103.62M | $-94.70M | $-89.17M | $688.54M | $-105.57M | $-89.04M | $-70.49M | $-6.38M | $-71.16M | $-80.98M | $-55.30M | $37.77M | $-18.93M | $-37.73M | $-35.37M | $140.04M | $-44.37M | $-40.14M | $96.18M | $-1.70M | $5.24M |
| Low Forecast | $-170.10M | $-206.05M | $-215.11M | $-195.70M | $-198.67M | $-227.69M | $-187.10M | $-147.13M | $-175.38M | $-175.03M | $-178.59M | $-133.75M | $459.03M | $-105.57M | $-89.04M | $-105.73M | $-6.38M | $-71.16M | $-80.98M | $-82.96M | $37.77M | $-18.93M | $-37.73M | $-53.05M | $140.04M | $-44.37M | $-40.14M | $64.12M | $-2.56M | $3.50M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.98% | 0.65% | 1.11% | -0.09% | 0.45% | 1.18% | 0.74% | -35.23% | 1.16% | 1.00% | 1.30% | -9.01% | 1.63% | 0.84% | 1.09% | 1.32% | -0.59% | 0.02% | 1.05% | 0.67% | 0.79% |
Ionis Pharmaceuticals's average Quarter net income forecast for Mar 22 is $-88.11M, with a range of $-105.73M to $-70.49M. IONS's average Quarter net income forecast represents a -139.23% decrease compared to the company's last Quarter net income of $224.61M (Dec 21).
Ionis Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 14 | 9 | 7 | 4 | 9 | 15 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 7 | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 | 15 |
| SG&A | - | - | - | - | - | - | - | - | - | $69.95M | $46.14M | $46.00M | $48.00M | $34.40M | $33.80M | $34.10M | $38.60M | $30.10M | $45.10M | $57.10M | $138.84M | $68.45M | $72.02M | $74.99M | $83.28M | $60.04M | $75.11M | $68.22M | $43.65M | $13.68M |
| Avg Forecast | $65.21M | $48.48M | $46.20M | $40.39M | $43.05M | $39.48M | $47.56M | $64.16M | $53.05M | $41.70M | $42.79M | $58.33M | $98.61M | $43.86M | $42.82M | $46.11M | $83.95M | $48.79M | $39.35M | $43.92M | $83.62M | $55.49M | $45.36M | $68.74M | $124.02M | $46.86M | $44.27M | $64.75M | $65.48M | $17.23M |
| High Forecast | $83.32M | $61.95M | $59.04M | $46.56M | $58.82M | $40.61M | $48.13M | $76.99M | $63.08M | $50.73M | $54.68M | $69.99M | $118.33M | $43.86M | $42.82M | $55.33M | $83.95M | $48.79M | $39.35M | $52.71M | $83.62M | $55.49M | $45.36M | $82.49M | $124.02M | $46.86M | $44.27M | $77.70M | $78.58M | $20.68M |
| Low Forecast | $51.25M | $38.10M | $36.32M | $30.28M | $34.76M | $38.34M | $46.99M | $51.33M | $39.01M | $36.99M | $33.63M | $46.66M | $78.88M | $43.86M | $42.82M | $36.89M | $83.95M | $48.79M | $39.35M | $35.14M | $83.62M | $55.49M | $45.36M | $55.00M | $124.02M | $46.86M | $44.27M | $51.80M | $52.38M | $13.79M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.68% | 1.08% | 0.79% | 0.49% | 0.78% | 0.79% | 0.74% | 0.46% | 0.62% | 1.15% | 1.30% | 1.66% | 1.23% | 1.59% | 1.09% | 0.67% | 1.28% | 1.70% | 1.05% | 0.67% | 0.79% |
Ionis Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $53.05M, based on 9 Wall Street analysts, with a range of $39.01M to $63.08M. The forecast indicates a -24.16% fall compared to IONS last annual SG&A of $69.95M (Sep 23).
Ionis Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 14 | 9 | 7 | 4 | 9 | 15 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 7 | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | $-1.03 | $-0.60 | $-0.87 | $-0.37 | $-0.33 | $-0.74 | $-0.46 | $1.59 | $-0.58 | $-0.57 | $-0.64 | $-2.44 | $-0.22 | $-0.23 | $-0.35 | $1.31 | $0.19 | $-0.01 | $0.63 | $-0.01 | $0.03 |
| Avg Forecast | $-0.84 | $-1.02 | $-1.06 | $-1.11 | $-1.10 | $-1.13 | $-0.93 | $-1.04 | $-0.80 | $-1.01 | $-0.88 | $-0.87 | $-0.94 | $-0.72 | $-0.61 | $-0.69 | $-0.04 | $-0.49 | $-0.55 | $-0.51 | $0.26 | $-0.13 | $-0.26 | $-0.14 | $0.96 | $-0.30 | $-0.28 | $0.61 | $-0.05 | $0.06 |
| High Forecast | $-0.61 | $-0.74 | $-0.77 | $-0.99 | $-0.72 | $-0.81 | $-0.67 | $-0.75 | $-0.29 | $-0.70 | $-0.64 | $-0.63 | $-0.68 | $-0.72 | $-0.61 | $-0.69 | $-0.04 | $-0.49 | $-0.55 | $-0.51 | $0.26 | $-0.13 | $-0.26 | $-0.14 | $0.96 | $-0.30 | $-0.28 | $0.61 | $-0.04 | $0.08 |
| Low Forecast | $-1.14 | $-1.39 | $-1.45 | $-1.32 | $-1.34 | $-1.53 | $-1.26 | $-1.41 | $-1.18 | $-1.18 | $-1.20 | $-1.18 | $-1.28 | $-0.72 | $-0.61 | $-0.69 | $-0.04 | $-0.49 | $-0.55 | $-0.51 | $0.26 | $-0.13 | $-0.26 | $-0.14 | $0.96 | $-0.30 | $-0.28 | $0.61 | $-0.05 | $0.05 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.02% | 0.68% | 1.00% | 0.39% | 0.46% | 1.21% | 0.67% | -36.40% | 1.19% | 1.03% | 1.26% | -9.43% | 1.70% | 0.89% | 2.58% | 1.37% | -0.63% | 0.04% | 1.04% | 0.20% | 0.50% |
According to 13 Wall Street analysts, Ionis Pharmaceuticals's projected average Quarter EPS for Mar 22 is $-0.69, with a low estimate of $-0.69 and a high estimate of $-0.69. This represents a -143.22% decrease compared to IONS previous annual EPS of $1.59 (Dec 21).
Ionis Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| APLS | Apellis Pharmaceuticals | $27.75 | $74.50 | 168.47% | Buy |
| IOVA | Iovance Biotherapeutics | $8.24 | $21.00 | 154.85% | Buy |
| TERN | Terns Pharmaceuticals | $5.71 | $14.25 | 149.56% | Buy |
| ARWR | Arrowhead Pharmaceuticals | $18.28 | $45.38 | 148.25% | Buy |
| VKTX | Viking Therapeutics | $51.63 | $102.40 | 98.33% | Buy |
| BMRN | BioMarin Pharmaceutical | $63.45 | $101.70 | 60.28% | Buy |
| SRPT | Sarepta Therapeutics | $110.50 | $169.06 | 53.00% | Buy |
| IONS | Ionis Pharmaceuticals | $33.94 | $51.68 | 52.27% | Buy |
| AKRO | Akero Therapeutics | $31.20 | $46.00 | 47.44% | Buy |
| HALO | Halozyme Therapeutics | $45.70 | $57.00 | 24.73% | Buy |
| INCY | Incyte | $70.39 | $84.56 | 20.13% | Buy |
| PTCT | PTC Therapeutics | $42.89 | $46.50 | 8.42% | Hold |
| KRYS | Krystal Biotech | $182.29 | $191.00 | 4.78% | Buy |
| ALNY | Alnylam Pharmaceuticals | $246.80 | $254.21 | 3.00% | Buy |
| MDGL | Madrigal Pharmaceuticals | $329.24 | $315.75 | -4.10% | Buy |
| EXEL | Exelixis | $34.83 | $30.50 | -12.43% | Buy |